Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Xanodyne Pharmaceuticals (Roxicodone)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Oxycodone hydrochloride tablets in 5, 15 and 30 mg dosage strengths. Roxicodone is an immediate release formulation of oxycodone indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. It is marketed in the United States.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • 1 Riverfront Place
  • Newport, KY 41071
  • United States

Xanodyne Pharmaceuticals (Roxicodone) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Xanodyne Pharmaceuticals (Roxicodone)‘s full profile, request access.

Request full access to PitchBook

Xanodyne Pharmaceuticals (Roxicodone) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Xanodyne Pharmaceuticals (Roxicodone)‘s full profile, request access.

Request full access to PitchBook